Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
Wolfgang Miesbach/LinkedIn
Mar 17, 2026, 15:45

Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Kerstin Herbst et al, published in Haemophilia:

“One single infusion.

Normal Factor VIII for six years – even after Grade 3 ALT elevation.

A new case report about a remarkable 6-year follow-up of a patient with severe haemophilia A treated with valoctocogene roxaparvovec within the GENEr8-1 study.

Six full years after a single gene therapy infusion, the patient maintains normal FVIII activity (49-72 IU/dL by chromogenic assay in year 6) – with zero bleeding episodes and no prophylactic FVIII infusions since treatment.

FVIII levels appear to have reached a plateau from year 3 onwards, pointing to durable, long-term transgene expression.

What makes this case particularly instructive is the immunosuppression management:

  • Grade 3 ALT elevation (peak 555 U/L) at week 5 required hospitalisation and IV methyl-prednisolone
  • Oral prednisolone was switched to budesonide to reduce systemic side effects (incl. oral thrush) – while FVIII levels remained protected
  • Total immunosuppression lasted approximately 40 weeks – personalised, stepwise, and carefully tapered

For context: in the GENEr8-1 trial overall, only 8.3% of patients maintained FVIII more than 40 IU/dL at 5 years.

This case demonstrates that with tailored immunosuppression, significantly better long-term outcomes are within reach – even after a serious hepatic immune response.

Congratulations to Kerstin Herbst, Behnaz Pezeshkpoor and co-authors from the University of Bonn (Johannes Oldenburg).”

Title: Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels

Authors: Kerstin Herbst, Behnaz Pezeshkpoor, Claudia Klein, Thilo Albert, Philipp Lutz, Christian Strassburg, Ulrich Spengler, Georg Goldmann, Johannes Oldenburg

Read the Full Article on Haemophilia

Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A

Simon Fletcher, Research Assistant at University of Oxford, shared this post, adding:

“An interesting paper, but yet again, there is no discussion of the psychosocial impacts of either the gene therapy itself or the immunosuppression required to treat the ALT elevation.

Case reports are important but they should be more than just a report of the physical outcomes to a treatment or incident.”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.

 

Behnaz Pezeshkpoor bleeding disorders Christian Strassburg Claudia Klein Gene therapy Georg Goldmann haemophilia haemophilia A Health Hematology Hemostasis Hemostasis News Hemostasis Today Immunosuppression Johannes Oldenburg Kerstin Herbst Medicine Philipp Lutz severe haemophilia A Thilo Albert Ulrich Spengler Wolfgang Miesbach
NewsFeed